At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 111 enrolled
Drug / intervention
SGX942 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating SGX942 and Placebo for Oral Mucositis. Completed, enrolled 111 participants across 1 site.
Detailed Summary
To evaluate the safety and efficacy of SGX942 in patients receiving chemoradiation treatment for the treatment of head and neck cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Mucositis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionDec 2015
Study CompletionSep 2016
TodayJul 2026
First PostedDec 17, 2013
Enrollment StartDec 1, 2013
Primary CompletionDec 1, 2015
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.5 years ago
Interventions
SGX942drug
Placebodrug